Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE wants more info on Roche's MabThera for rare autoimmune disease

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal institute for England and Wales, is so far "minded not" to recommend Roche's MabThera (rituximab) for National Health Service patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. However, Roche could still convince the institute to, say yes. It has asked for more information from ahead of the next appraisal meeting on 28 August .

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC022181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel